Basic Colofac Information

• INN (International Nonproprietary Name): Mebeverine
• Brand Names Available In United Kingdom: Colofac®, Aurobeverine®; tablets 135 mg, modified‑release capsules 200 mg, and oral liquid formulations.
• ATC Code: A03AA04 — Drugs for functional gastrointestinal disorders, synthetic anticholinergics, esters with tertiary amino group.
• Forms & Dosages Sold: Standard tablets 135 mg (one tablet three times daily); prolonged‑release capsules 200 mg (one capsule twice daily); oral liquid equivalents for swallowing difficulties.
• Manufacturers In United Kingdom: Major originator and suppliers include Abbott/Mylan (now Viatris) and generics from companies active in Europe such as Teva, Sanofi and Zentiva.
• Registration Status In United Kingdom: MHRA authorised for both OTC small packs and prescription dispensing for Colofac and generic mebeverine products.
• OTC / Rx Classification: Available OTC in small packs in some UK pharmacies; larger supplies are typically supplied on prescription.

Key Findings From Recent Trials

Worried that new evidence has overturned what pharmacists have always heard about Colofac?

High‑quality systematic reviews and earlier randomised controlled trials remain the main evidence base for mebeverine.

Since 2022 there have been relatively few new large placebo‑controlled RCTs focused solely on mebeverine.

Instead the recent signal comes from network meta‑analyses, comparative antispasmodic trials and real‑world pharmacy outcome data.

Overall the trend is toward small‑to‑moderate improvements versus placebo for global IBS symptoms.

The clearest benefit is for cramp‑related abdominal pain rather than normalising bowel habit.

Major 2022–2025 Studies

What new trials should clinicians know about?

There were few large new placebo‑controlled studies of mebeverine in the UK between 2022 and 2025.

Network meta‑analyses pooled older RCTs with newer comparative trials to place mebeverine among antispasmodics for IBS symptom control.

Real‑world pharmacy outcomes tracked patient‑reported pain relief and adherence with 135 mg tablets and 200 mg MR capsules.

Comparative trials often contrasted mebeverine with other antispasmodics such as hyoscine butylbromide and dicycloverine.

These comparative data support mebeverine as a tolerable option with modest efficacy for cramp relief.

Main Outcomes

How much symptom improvement can patients expect?

Most studies show improvements in daily pain scores and patient‑reported global relief over weeks of treatment.

Benefits are most consistent when Colofac is used at licensed UK dosing — 135 mg three times daily or 200 mg MR twice daily.

The greatest symptom change is seen for sudden cramping and focal abdominal pain rather than for bowel frequency or stool form.

Combining mebeverine with diet and lifestyle measures tends to produce more reliable improvements.

Safety Observations

Should safety concerns limit use in primary care or OTC settings?

Post‑marketing surveillance and product information report rare hypersensitivity reactions such as rash or angioedema.

Occasional gastrointestinal upset, dizziness and headache are listed among the uncommon adverse effects.

No major systemic anticholinergic profile has been observed, which supports tolerability versus traditional antimuscarinics.

UK regulatory practice and MHRA‑authorised OTC availability in small packs reflect a favourable safety profile for short‑term use.

Clinical Mechanism Of Action

How does Colofac actually reduce abdominal cramps?

Layman’s Explanation

Colofac relaxes the muscle wall of the gut to ease crampy, stabbing abdominal pain.

Patients usually report fewer sudden spasms and better tolerance of meals when symptoms are spasm‑driven.

The medicine does not commonly cause the dry mouth or blurred vision typical of classic anticholinergics.

Scientific Breakdown

What is known about mebeverine at a physiological level?

Mebeverine is classified under ATC A03AA04 as a synthetic anticholinergic ester with a tertiary amino group.

Its primary action appears to be a direct smooth‑muscle relaxant effect on the intestinal wall rather than systemic muscarinic blockade.

Proposed mechanisms include membrane stabilisation of enteric smooth muscle and inhibition of abnormal contractions.

These effects may be mediated by modulation of calcium handling and local enteric neurotransmitters.

Minimal central nervous system penetration is reported, which fits the low systemic anticholinergic profile noted in product information.

Pharmacokinetics are formulation dependent with standard 135 mg tablets and 200 mg modified‑release capsules available in the UK.

Licensed dosing regimens are 135 mg three times daily or 200 mg MR twice daily, with liquid forms for those with swallowing difficulties.

Scope Of Approved And Off‑Label Use

Can Colofac be used for anything beyond classic IBS?

United Kingdom Approvals

MHRA authorises Colofac (mebeverine) for symptomatic relief of abdominal pain, cramps and bowel irregularity in irritable bowel syndrome.

Licensed forms in the UK include 135 mg tablets, 200 mg modified‑release capsules and oral liquid.

Small OTC packs are available in community pharmacies alongside prescription supplies for longer courses.

Notable Off‑Label Trends

When do clinicians choose mebeverine outside the licence?

UK and European clinicians sometimes prescribe mebeverine for non‑specific gut spasms and functional abdominal pain syndromes beyond classical IBS.

Use is attractive when patients are sensitive to anticholinergic side effects of alternatives such as dicycloverine.

Mebeverine is generally not recommended for children under 10 years because of limited safety data.

Pregnancy and breastfeeding lack robust controlled data, so off‑label use is cautious and typically avoided unless clearly justified.

Because it is non‑habit forming and well tolerated, GPs may trial mebeverine before escalating to antimuscarinic agents or psychological strategies for refractory IBS.

Dosage Strategy

What dose should patients start on and when should they be reviewed?

General Dosing

Standard adult dosing in the UK is 135 mg tablet three times daily or 200 mg modified‑release capsule twice daily.

Liquid preparations are available for people who struggle with tablets.

If a dose is missed, patients should take it as soon as they remember unless the next dose is due soon and must not double up.

Condition‑Specific Dosing

How long should a trial of Colofac last in IBS with cramps?

For IBS with predominant cramping or pain start standard licensed dosing for 2–4 weeks to assess response.

135 mg tablets taken TID are the common maintenance choice, while 200 mg MR capsules twice daily offer better adherence for some patients.

If symptoms persist after about two weeks a clinical review is recommended rather than automatic dose escalation.

Special populations such as the elderly usually receive standard doses unless comorbidity requires caution.

No formal hepatic or renal dose adjustments are specified, but use caution in severe impairment owing to limited data.

Safety Protocols

What should pharmacists check before recommending Colofac?

Contraindications

Absolute contraindications include hypersensitivity to mebeverine or any excipients and known paralytic ileus.

Certain formulations should not be used in hereditary galactose intolerance, Lapp lactase deficiency or glucose‑galactose malabsorption.

Adverse Effects

Which side effects should patients be warned about?

Hypersensitivity reactions such as rash, urticaria or angioedema are reported and require immediate discontinuation.

Gastrointestinal complaints including heartburn, indigestion, diarrhoea or constipation are uncommon but possible.

CNS effects such as dizziness, headache, tiredness and insomnia have been reported rarely.

Very rare events listed include decreased pulse rate, drug‑induced angle‑closure glaucoma and false positives for amphetamines in some urine drug screens.

Advise patients to stop treatment and seek urgent review if they develop rash, facial swelling, visual disturbance or severe abdominal pain.

For OTC supply in the community, provide safety counselling and recommend GP review if no benefit is seen after two weeks.

Interaction Mapping

Will Colofac interact with my other medicines or food?

Food Interactions

Product information does not list significant food interactions and Colofac may be taken with or without food.

Advise patients to keep timing consistent relative to meals if symptoms are meal‑related so they can assess benefit accurately.

Drug Combinations To Avoid

Are there drug–drug concerns to flag at the pharmacy counter?

Mebeverine shows minimal clinically significant drug–drug interactions in available data.

There is no major CYP enzyme interaction signal in routine product information.

Inform patients undergoing drug testing that rare false‑positive urine amphetamine screens have been reported.

Exercise caution when co‑prescribing with medicines affecting cardiac conduction in people with pre‑existing cardiac conditions because rare bradycardia has been reported.

Although systemic anticholinergic activity is low, review the combined anticholinergic burden if other antimuscarinic agents are being used.

Always check concomitant medicines in community pharmacy to reassure about low interaction risk and to flag rare scenarios requiring monitoring.

Patient Experience Analysis

Do people actually feel better when they try Colofac?

Survey Data

Primary care patient surveys show many users report reduced cramp severity and improved daily comfort when taking mebeverine at licensed doses.

Objective changes in bowel frequency or stool form are less consistent across respondents.

Adherence is higher with the 200 mg MR twice‑daily formulation due to convenience.

Small OTC packs increase early access and encourage self‑management for patients with intermittent symptoms.

Forum Trends

What do people say online about Colofac?

UK forums commonly report positive anecdotes for cramp relief, notably from patients who cannot tolerate classic anticholinergic side effects.

Negative comments usually concern lack of benefit in diarrhoea‑predominant IBS or persistent bloating despite treatment.

Many forum users combine mebeverine with dietary changes such as low FODMAP approaches, probiotics or fibre therapy.

Clinically, set expectations about modest benefit for pain and variable effects on stool form, and emphasise the importance of a defined trial period and GP review.

Distribution And Pricing Landscape

Where can I buy Colofac and how much will it cost me?

Colofac and generics are widely available in UK community pharmacies and online retailers under brand names including Colofac® and Aurobeverine®.

Formats commonly stocked are 135 mg tablets, 200 mg modified‑release capsules and oral liquids for those with swallowing difficulties.

As a long‑established generic molecule, mebeverine pricing in the UK is competitive compared with other antispasmodics.

OTC small packs carry a retail price similar to other OTC antispasmodics, while prescription dispensing cost varies with NHS formulary sourcing.

Bulk or MR capsule formats can be more cost‑effective per dose for chronic users, but community pharmacists should check pack sizes when advising on cost.

Supply is generally stable in the UK, though patients may see brand substitution between generics and should be counselled accordingly.

In our online pharmacy, colofac is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

What are realistic alternatives if Colofac is unsuitable or ineffective?

Comparison Table

Common alternatives include dicycloverine (dicyclomine), hyoscine butylbromide (Buscopan®), peppermint oil (Colpermin®) and alverine citrate (Spasmonal®).

Choice depends on predominant symptoms, anticholinergic sensitivity and patient comorbidities.

Pros And Cons

How does mebeverine compare in practice?

• Mebeverine (Colofac): Pros — well tolerated, low systemic anticholinergic effects, non‑habit forming, OTC small packs, MR options for adherence. Cons — modest efficacy for stool normalisation and limited data in pregnancy and young children.
• Dicycloverine: Pros — antispasmodic effect for cramp relief. Cons — anticholinergic side effects such as dry mouth and blurred vision can be problematic.
• Hyoscine Butylbromide: Pros — rapid onset for acute colic. Cons — anticholinergic burden and variable OTC availability.
• Peppermint Oil: Pros — trial evidence for IBS symptom relief in some studies. Cons — risk of heartburn and inconsistent product quality across brands.

Clinical tip: consider mebeverine for patients who are sensitive to anticholinergic effects and use peppermint oil or combination strategies where broader symptom coverage is required.

Regulatory Status

What do regulators in the UK and abroad say about mebeverine?

MHRA authorises Colofac and generic mebeverine products for OTC and prescription dispensing in the UK, with standard labelling and storage instructions.

Internationally the medicine is registered in many countries, including TGA Australia where it is prescription‑only and Medsafe New Zealand with consumer and prescriber information available.

The ATC classification for mebeverine is A03AA04 and several originator and generic manufacturers supply the global market.

Healthcare professionals should report significant adverse events through the Yellow Card scheme in the UK as part of ongoing pharmacovigilance.

Consolidated FAQ

What are the quick answers patients and clinicians ask most?

Common Patient Questions

How quickly does Colofac work?

Many patients notice cramp relief within days, but assess over 2–4 weeks for meaningful improvement.

Is Colofac safe long‑term?

It is non‑habit forming and long‑term use is acceptable under medical supervision.

Can I buy it OTC?

Small packs are available OTC in UK pharmacies, while larger supplies are generally prescription only.

Clinician FAQs

When should a clinician review therapy?

If there is no noticeable benefit after around two weeks a review of diagnosis and treatment strategy is recommended.

What about pregnancy and breastfeeding?

Data are limited, so avoid unless clinically necessary and after weighing risks and benefits.

Are there important drug interactions?

Clinically significant interactions are minimal, but be aware of rare urine drug‑screen false positives and monitor cardiac risk where relevant.

Practical pointer: always combine mebeverine with lifestyle advice such as low FODMAP dietary measures when appropriate and consider psychological or physiotherapy approaches for refractory cases.

Visual Guide

Which visual elements help patients understand use and expectations?

Suggested Infographic Elements

Include header “Colofac (Mebeverine) At A Glance”, dosing comparison (135 mg TID vs 200 mg MR BD) and simple icons for tablet, MR capsule and liquid formulations.

Show approved indication panels for IBS pain and cramps, highlight contraindications and rare safety points, and a small map or note indicating UK OTC small‑pack availability.

Chart And Data To Include

What quick data visualisations improve comprehension?

A bar chart comparing percent of patients reporting pain reduction versus placebo using pooled analysis labelled as “modest benefit” is useful.

A pie chart showing distribution of common adverse reaction categories (GI, immune, CNS) based on product information aids safety counselling.

Include a simple flowchart for “When To Review” that flags red‑flag symptoms requiring urgent referral.

Storage And Transport

How should patients store and carry their medicine?

Store Colofac in the original blister packaging below 25°C, protected from moisture and light.

Keep all medicines out of reach of children and do not use after the printed expiry date.

For online orders to UK addresses ship under standard ambient conditions and avoid despatch in extreme heat where possible.

Advise patients to return unused or expired medication to a pharmacy for safe disposal rather than binning at home.

Guidelines For Proper Use

What checklist should prescribers and pharmacists follow before recommending Colofac?

Prescribing Checklist

Confirm an IBS diagnosis and exclude red flags such as unexplained weight loss, GI bleeding or new‑onset symptoms over 50 years.

Check for allergy history and contraindications including paralytic ileus and relevant hereditary carbohydrate intolerances.

Choose a formulation based on adherence and swallowing ability — 135 mg TID tablets or 200 mg MR BD capsules are the standard options.

Set a review timeline of about two weeks and advise reporting of adverse events to the Yellow Card scheme.

Patient Counselling Points

What should patients hear at the pharmacy counter?

Explain realistic expectations: mebeverine works best for cramp relief and has a variable effect on stool form.

Demonstrate dosing, missed‑dose advice and storage, and advise when to seek medical review for worsening pain, rash or visual problems.

Recommend combining the medicine with dietary measures, psychological therapies or IBS‑specific physiotherapy if symptoms persist.

Delivery Across United Kingdom

City	Region	Delivery Time
London	England	5-7 days
Birmingham	England	5-7 days
Manchester	England	5-7 days
Glasgow	Scotland	5-7 days
Leeds	England	5-7 days
Liverpool	England	5-7 days
Edinburgh	Scotland	5-7 days
Bristol	England	5-7 days
Sheffield	England	5-9 days
Cardiff	Wales	5-9 days
Belfast	Northern Ireland	5-9 days
Newcastle Upon Tyne	England	5-9 days

Summary: Colofac (mebeverine) is a well‑tolerated antispasmodic authorised in the UK for relief of abdominal pain and cramps in IBS.

Expect modest benefit for cramp relief, variable effects on stool form and a low systemic anticholinergic profile compared with older antimuscarinics.

For community pharmacy supply, advise a defined 2–4 week trial, watch for hypersensitivity and advise GP review if symptoms persist or red flags appear.

Report any significant adverse events through the Yellow Card scheme to support ongoing pharmacovigilance in the UK.